Today we announce that GSK has completed its acquisition of Aiolos Bio. We are excited that GSK will deploy its resources and deep respiratory expertise to accelerate the development of AIO-001 in asthma and potentially other indications. See press release for more details: https://lnkd.in/gsvaZNTq
About us
At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immunological disorders. Our goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden. Our vision is embodied in our current focus – the development of a groundbreaking anti-TSLP therapy with best-in-class potential. We are a San Francisco Bay area-based clinical stage biopharma company with additional operations in London, UK. The Aiolos team is comprised of seasoned drug developers, who have successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more. As we grow, we will look to add like-minded individuals to our team - those committed to the goal of providing a meaningful difference in the lives of patients suffering from respiratory illnesses and other immune disorders.
- Website
-
AiolosBio.com
External link for Aiolos Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Get directions
San Francisco, CA, US
-
Get directions
London, GB
Employees at Aiolos Bio
-
Glenn Whelan
Senior Director, Clinical Development
-
Rene van der Merwe
Chief Medical Officer at Aiolos Bio
-
Dan Milam, EMBA
Establishing collaborative relationships with clinical research sites and healthcare organizations to bring affordable medicines to all patients.
-
Maha Katabi, PhD, CFA
General Partner at Sofinnova Investments
Updates
-
Today we are proud to announce a definitive merger agreement under which GSK will acquire Aiolos Bio for a total value of $1.4B. This deal will enable us to advance our mission of helping patients breathe easier and reducing their treatment burden by capitalizing on GSK’s global scale and considerable experience in developing and commercializing respiratory therapies. We are incredibly proud of what we have accomplished and can’t think of a better partner to help take AIO-001 into its next stage of development. To learn more please click here: https://lnkd.in/ghwpPhGv
-
Aiolos is thrilled to welcome to the team Rene van der Merwe as Chief Medical Officer, and Tapan Maniar as Chief Business Officer. Their combined experience and roles as key members of our #leadership team will serve Aiolos well as we prepare to initiate a Phase 2 #clinicaltrial for our lead drug candidate for the treatment of severe #asthma while continuing to build out our operations. To learn more about the Aiolos team and our patient-centric mission, visit: https://lnkd.in/dPQKZ_wV
Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments
businesswire.com
-
Aiolos Bio, Inc. is excited to announce our launch as a clinical-stage biopharmaceutical company dedicated to addressing the unmet needs of patients with respiratory and inflammatory conditions. With an accomplished team brought together by our founder CEO Khurem Farooq and Co-Founder Tony Adamis, an esteemed group of investors supporting our mission, and the potential of our lead drug candidate to be a best-in-class anti-TSLP therapy, we see a unique opportunity to positively impact patients’ asthma outcomes. In addition, we are thrilled to have the leadership of industry veteran @John Milligan who will assume the role of Board Chair at Aiolos Bio. Join us on our exciting journey! #Biopharma #Innovation #RespiratoryHealth #ClinicalTrials https://lnkd.in/gDeBZV5t
Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody
businesswire.com